Every 10-Q that Sonoma Pharmaceuticals, Inc. (SNOA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SNOA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNOA filings page.
Sonoma Pharmaceuticals reported strong improvement for the quarter ended June 30, 2026. Revenue rose to $6,406,000, up from $4,015,000 a year earlier, a 60% increase, with 141% growth in the United States and double‑digit gains across Europe, Asia, Latin America and other regions. Gross profit increased to $2,577,000 and gross margin expanded to 40% from 36%.
The company narrowed its net loss to $330,000, or $0.09 per share, from $1,241,000, as research and development and selling, general and administrative costs grew only modestly. Operating cash outflow improved to $649,000 from $2,015,000. Equity issuance, including an underwritten unit offering and at‑the‑market sales, generated $3,536,000 of net proceeds, lifting cash to $5,338,000 and working capital to $10,821,000; management believes this, together with existing resources, will fund projected needs for at least twelve months.
Common shares outstanding increased sharply to 4,785,801, and 3,407,404 new warrants to purchase common stock were issued, creating meaningful potential dilution. The company also discloses sizable Mexico intercompany loans, accrued interest and related tax and withholding exposures, and notes new Nasdaq Market Value of Listed Securities requirements that could heighten delisting risk if thresholds are not met.
Sonoma Pharmaceuticals reported higher sales but continued losses for the quarter ended December 31, 2025. Quarterly revenue rose 22% to $4.35 million, driven by strong growth in the United States, Europe and Asia, while Latin America declined.
Gross profit increased to $1.65 million, with gross margin improving slightly to 38%. Operating expenses were stable, producing a smaller net loss of $0.82 million, or $0.48 per share, compared with a loss of $0.63 per share a year earlier.
For the first nine months of the fiscal year, revenue grew 33% to $13.97 million and net loss narrowed modestly to $2.59 million. Cash and cash equivalents fell to $2.56 million, and operating cash outflow was $3.41 million. Management disclosed that recurring losses and funding needs create substantial doubt about the company’s ability to continue as a going concern without additional capital.
Sonoma Pharmaceuticals (SNOA) reported Q2 FY2026 results. Revenue was $5.604 million, up 57% year over year, with gross profit of $2.120 million and a gross margin of 38%. Net loss narrowed to $0.534 million (basic and diluted EPS $(0.32)) from a $0.610 million loss a year ago.
Six-month performance: Revenue reached $9.619 million, up 38% year over year, with gross profit of $3.584 million and a 37% margin. Operating expenses were $2.457 million in Q2 and $5.016 million for the first half.
Cash and liquidity: Cash and equivalents were $3.035 million at September 30, 2025, and net cash used in operating activities was $2.650 million for the six months. Working capital was $8.179 million. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern within one year without additional capital. Subsequent to quarter end, the company sold 51,436 shares via its at-the-market program for gross proceeds of $232,000 and net proceeds of $170,000. Shares outstanding were 1,701,076 as of November 3, 2025.